8th Jun 2015 07:17
CANONSBURG (Alliance News) - Mylan NV Monday said that it has launched what it claims is the first bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler under the brand name Sirdupla in the UK.
Sirdupla is a pressurized metered-dose inhaler and is indicated to help treat or prevent symptoms of asthma in adults 18 years of age and older. The product is being manufactured by 3M Drug Delivery Systems.
Sirdupla is a daily maintenance pressurized metered-dose inhaler that offers the same ease of use that patients expect from their asthma therapy. It is available in 125/25 mcg and 250/25 mcg with 120 doses.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline